Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.CV Therapeutics has announced that an analysis of data on 2,291 women who participated in the MERLIN TIMI-36 study showed a 29% reduction in the relative risk of recurrent ischemia in women receiving Ranexa compared to placebo after 12 months.
Subscribe to our email newsletter
MERLIN TIMI-36 (metabolic efficiency with ranolazine for less ischemia in non-ST elevation acute coronary syndromes) was a multi-national, double-blind, randomized, placebo-controlled, parallel-group clinical trial designed to evaluate the efficacy and safety of Ranexa during acute and long-term treatment in 6,560 patients (3,279 received ranolazine, 3,281 received placebo) with non-ST elevation acute coronary syndromes treated with standard therapy.
Louis Lange, chairman and CEO of CV Therapeutics, said: “Women were very well represented in the MERLIN TIMI-36 study and these data provide important additional confirmation of the safety and efficacy we have seen with Ranexa in other clinical trials and in commercial use.”